Serious adverse events and compensation in registration trials: a review of data from a Japanese university hospital

BMC Research Notes

Hiroaki Yanagawa¹  Kazuo Minakuchi²  Makiko Yamagami¹  Toshiko Miyamoto¹  Rumi Katashima¹  Soichiro Tajima¹  Miho Watanabe¹ 

[1]Clinical Trial Center for Developmental Therapeutics, Tokushima University Hospital, Kuramoto-cho 2, Tokushima 770-8503, Japan

[2]Institutional Review Board, Tokushima University Hospital, Kuramoto-cho, Tokushima, Japan

关键词: Oncology;    Clinical research coordinator;    Compensation;    Serious adverse events;    Registration trial;   

Others  :  1133432
DOI  :  10.1186/1756-0500-7-245

 received in 2013-11-21, accepted in 2014-04-11,  发布年份 2014

【 摘 要 】

Background

Clinical trials leading to regulatory approval, or registration trials, play a central role in the development of drugs and medical devices. The contribution of support staff, such as the clinical research coordinator (CRC) and administrative officers, in registration trials is now widely recognized. Attending to serious adverse events is an important duty of the CRC and investigators alike, and managing these complications and compensation constitutes a key responsibility. We retrospectively examined the frequency of serious adverse events and compensation events reported from 2007 through 2011 at Tokushima University Hospital, an academic hospital in rural Japan. We present herein the results of our analysis.

Results

Over the five-year period, 284 subjects participating in 106 registration trials experienced a total of 43 serious adverse events, and eight compensation events were documented. Among the serious adverse events, 35 (81.4%) were considered not related to the investigational drug, and 17 (39.5%) resulted in withdrawal of the study drug. Patients with malignant diseases experienced serious adverse events significantly more frequently compared to those with non-malignant diseases (28.3% versus 8.2%, respectively; P < 0.01).

Conclusions

The CRC should be vigilant for serious adverse events in oncology clinical trials due to the generally higher frequency of these complications in subjects with malignancy. However, on an individual basis, the CRC may be seldom involved in the process for compensating serious adverse events. Therefore, the CRC’s ability to share such experiences may serve as an opportunity for educating clinical trial support staff at the study site as well as those at other sites. However, further study is warranted to determine the role of the clinical trial support staff in optimizing methods for managing adverse events requiring compensation in registration trials.

【 授权许可】

   
2014 Watanabe et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use: ICH Harmonised Tripartite Guideline. Clinical safety data management: Definitions and standards for expedited reporting E2A. [http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E2A/Step4/E2A_Guideline.pdf webcite]
• [2]Fukutomi J, Terada J, Koike N, Ishii K, Kimura K, Kobayashi S: St. Marianna Hospital ni okeru yuugaijishou heno taiou to hoshou. [Management of adverse events and compensation in St. Marianna University School of Medicine Hospital]. Jpn J Clin Pharmacol Ther 2002, 33:53-59.
• [3]Yamada N, Hirayama R, Matsuura K, Onda A, Kawai M, Ishizaki S, Nagamatsu A, Watanabe K, Toda C, Ogura K, Arakawa Y, Omata M: A manual to facilitate clinical data collection from the doctors in other hospitals whom subjects consult for serious adverse events during clinical trials. Jpn J Clin Pharmacol Ther 2008, 39:111-115.
• [4]Suzuki R, Iwasaki Y, Yamamoto Y, Asano K: Hoshou taiouniokeru CRC you checklist no sakusei to sono unnyou ni tuite [Development and application of CRC checklist for management of compensation]. Clin Res Professionals 2012, 28:30-33.
• [5]Poston RD, Buescher CR: The essential role of the clinical research nurse (CRN). Urol Nurs 2010, 30(1):55-63,77.
• [6]Steinbrook R: Compensation for injured research subjects. N Engl J Med 2006, 354:1871-1873.
• [7]Japan Pharmaceutical Industry Legal Affairs Association: Compensation guideline for injured research subjects. [http://www.ihoken.or.jp/guideline/2_revisionguidline.pdf webcite]
• [8]Ikegami N, Yoo BK, Hashimoto H, Matsumoto M, Ogata H, Babazono A, Watanabe R, Shibuya K, Yang BM, Reich MR, Kobayashi Y: Japanese universal health coverage: evolution, achievements, and challenges. Lancet 2011, 378:1106-1115.
• [9]Rico-Villademoros F, Hernando T, Sanz JL, López-Alonso A, Salamanca O, Camps C, Rosell R: The role of the clinical research coordinator – data manager – in oncology clinical trials. BMC Med Res Meth 2004, 4:6. BioMed Central Full Text